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Abstract
Introduction: Biological markers specifically reflecting pathological processes may add value in the assessment of
inter-individual variations in the course of rheumatoid arthritis (RA). The current study was undertaken to
investigate whether baseline serum levels of the chemokine CXCL13 might predict clinical and ultrasonographic
(US) outcomes in patients with recent-onset RA.
Methods: The study included 161 early RA patients (disease duration < 12 months) treated according to a disease
activity score (DAS) driven step-up protocol aiming at DAS < 2.4. Clinical disease activity measures were collected at
baseline, 2, 4, 6, 9 and 12 months, and US examination of the hands was performed at baseline, 6 and 12 months.
Grey-Scale (GS) and Power Doppler (PD) synovitis were scored (0 to 3), with overall scores as the sum of each joint
score. CXCL13 levels were measured at baseline by enzyme-linked immunosorbent assay and evaluated in relation to
the achievement of low disease activity (LDA, DAS < 2.4) and US residual inflammation (PD ≤ 1) at 12 months.
Results: Baseline levels of CXCL13 were significantly higher in RA compared to healthy controls (n = 19) (P = 0.03)
and correlated with measures of synovitis, such as the swollen joint count (R 0.28, P < 0.001), the US-GS (R 0.27, P
= 0.003) and US-PD (R 0.26, P = 0.005) score. Although CXCL13 did not predict the likelihood of achieving clinical
LDA at 12 months within a structured treat-to-target protocol, elevated levels of CXCL13 were associated with
more frequent increases of methotrexate dosage (P < 0.001). Using adjusted analyses, the highest levels of CXCL13
(> 100 pg/ml) were the only independent predictor of residual imaging inflammation (P = 0.005), irrespective of
initial US-PD scores, disease activity status, acute phase reactants and autoantibodies. Among the patients in clinical
LDA at 12 months, US-PD scores ≤ 1 were less frequently achieved in the high baseline CXCL13 (> 100 pg/ml)
group, with an adjusted OR = 0.06 (95% CI 0.01 to 0.55, P = 0.01).
Conclusions: CXCL13 emerges as a new biological marker in early RA, accurate in assessing the severity of
synovitis and the persistence of US-PD activity over time in response to conventional treatments.
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Introduction
Early intervention aiming at suppression of inflammation
through intensive steering strategies has remarkably
improved outcomes in rheumatoid arthritis (RA) [1,2].
Despite the general effectiveness, response to treatment is
highly variable and a substantial number of patients fail to
attain adequate clinical targets [3]. Achievement of clinical
remission itself may not coincide with true suppression of
inflammation, as patients in clinical remission may con-
tinue to have synovitis detectable using ultrasound (US)
[4]. In this context, the persistence of Power Doppler (PD)
activity may predict subsequent joint damage [5] and
short-term relapse [6] in disease-modifying anti-rheumatic
drug (DMARD)-treated patients in remission.
Prediction of the severity of joint inflammation at an
early stage is important to optimise treatment strategies in
patients with RA. Unfortunately, individual differences in
the course of the disease are not yet accurately explained
by traditional factors at baseline, including clinical disease
activity, the levels of acute-phase response and autoantibo-
dies [7-9]. Identification of new variables derived from
understanding pathogenic mechanisms that correlate
more specifically with synovitis, at both the clinical and
the sub-clinical level, might refine our ability to build early
prognostic algorithms.
The chemokine CXCL13 has features which make it
increasingly attractive as a biological marker in RA.
CXCL13 is involved in the positioning, cooperation and
activation of B and T cells within lymphoid and extra-lym-
phoid sites [10-12]. In RA synovium, ectopic expression of
CXCL13 associates with the local organisation of infiltrat-
ing lymphocytes and with the expression of activation-
induced cytidine deaminase, an enzyme sufficient and
required for somatic hypermutation and class-switch
recombination of immunoglobulin genes [13]. Supporting
its pathogenic significance, CXCL13 blockade improves
disease outcomes in animal models of arthritis [14].
Of relevance to translation from pathobiology to clinical
application, synovial CXCL13 mRNA has been recently
shown to co-vary with the level of local inflammatory bio-
marker expression and has been thus proposed as a surro-
gate marker of synovitis [15]. More importantly, the
possibility to detect and quantify the chemokine is not
restricted to relatively inaccessible compartments such as
the synovial membrane, but also involves the synovial fluid
and the peripheral circulation [15,16]. Preliminary results
indicate that serum CXCL13 protein levels and synovial
CXCL13 mRNA expression significantly correlate, sug-
gesting that the inflamed synovium may constitute an
important source of the circulating protein [15]. In line
with these data, serum CXCL13 has been proposed as a
biochemical marker reflecting the extent of inflammation
in a cross-sectional evaluation [17]. The promising value
of CXCL13 as a marker in clinical practice has been very
recently boosted by a prospective study demonstrating a
significant correlation between baseline serum levels and
the rate of joint destruction over long-term follow-up [18].
Despite the fact that preliminary data are encouraging,
the actual value of CXCL13 in the routine management
of RA remains unclear. Indeed, it is currently unknown
whether CXCL13 may provide accurate prediction of
the burden of the inflammatory process over time. The
aim of this study was to investigate whether CXCL13
levels assessed at baseline are associated with disease
activity outcomes over a 12-month follow-up in patients
with recent-onset RA within a structured treat-to-target
protocol. To ensure accurate assessment of joint inflam-
mation, disease activity was measured both clinically
and by US.
Materials and methods
Study participants and study protocol
Study subjects were 161 recent-onset RA patients
recruited from the Early Arthritis Clinic (EAC) of the Uni-
versity Hospital of Pavia based on the availability of base-
line serum. The Pavia EAC is a large prospective cohort as
previously described [6,19]. All patients followed a disease
activity score (DAS)-driven step-up therapeutic protocol
aimed at low disease activity (LDA: DAS < 2.4) based on
regular clinical assessment (every two months during the
first six months, then every three months). Parenteral
methotrexate (MTX) was used in monotherapy at the
initial dosage of 10 mg/week and progressively increased
to 25 mg/week if LDA was not met. Anti-tumour necrosis
factor (TNF) therapy was started in case of persistent dis-
ease activity above the LDA status despite maximal MTX
dosage. Prednisone 12.5 mg/day for two weeks and then
6.25 mg/day was randomly assigned at baseline as part of
an open-label therapeutic study on the efficacy of low
doses of prednisone in early arthritis involving a larger
cohort [19]. At study entry, all patients had a disease dura-
tion of less than one year and were DMARD- and gluco-
corticoid-naïve. The current analysis is based on follow-up
data at 12 months, which were available in 155 patients
(96%). Baseline characteristics of patients lost at follow-up
were not statistically different from those of patients with
complete data.
Local Ethical Committee (IRCCS Policlinico San Mat-
teo Foundation) approval was obtained, and all patients
signed written informed consent before study entry.
CXCL13 measurement
Serum samples were collected at baseline (before treat-
ment) and stored at -20°C until analysis. Serum aliquots
that had not been thawed before were used.
Measurement for CXCL13 levels was performed in tri-
plicate by colorimetric enzyme-linked immunosorbent
assay (ELISA) (R&D Systems, Minneapolis, MN, USA)
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according to the instructions of the manufacturer. Nine-
teen healthy subjects were included as controls. Median
values of CXCL13 in non-diseased individuals were
53.77 pg/ml (IQR 42.02 to 63.37), comparable to those
reported by others [17] and significantly different from
median values of RA patients in our cohort (72.74 pg/
ml, IQR 46.62 to 116.87, P = 0.03).
Clinical assessment
Patients’ characteristics collected at baseline included age,
sex, symptom duration, rheumatoid factor (RF) and anti-
citrullinated protein antibodies (ACPA) status and titres.
Clinical evaluation at each time point (0, 2, 4, 6, 9 and
12 months) included: the number of swollen and tender
joints on 44-joint count (SJC, TJC), Ritchie Articular
Index (RAI), Global Health assessment (GH) on a 0 to
100 mm Visual Analog Scale (VAS), evaluator global
assessment of disease activity (EGA) and patient global
assessment of disease activity (PGA) on a 0 to 10 cm VAS.
Erythrocyte sedimentation rate (ESR) and C-reactive pro-
tein serum levels (CRP) were also measured. At each visit,
the disease activity was measured by DAS based on ESR.
Baseline serum levels of CXCL13 were analysed in rela-
tion to the proportion of patients achieving LDA accord-
ing to DAS < 2.4 [20] at the end of follow-up. As a
secondary measure, remission rates (DAS < 1.6) were
also computed. Clinical outcomes were additionally
assessed through the Simplified Disease Activity Index
(SDAI) (LDA ≤ 11, remission ≤ 3.3) [21].
Ultrasonographic assessment
At baseline, 6 and 12 months US was performed by a sin-
gle experienced operator unaware of clinical data, using a
GE Logiq 9 scanner (General Electrics Medical Systems,
Milwaukee, WI, USA) with a multi-frequency linear array
transducer (10 to 15 MHz), according to the European
League Against Rheumatism (EULAR) guidelines [22].
The US assessment included transverse and longitudinal
scanning of medial and lateral dorsal view of bilateral
wrists (radiocarpal, ulno-carpal, radio-ulnar and midcar-
pal joints) and metacarpophalangeal joints, as previously
described [6]. Synovial PD was evaluated by selecting a
region that included bony margins, joint space and a vari-
able view of surrounding tissues. Pulse repetition fre-
quency (PRF) was adjusted at the lowest permissible to
maximise sensitivity. Colour gain was set just below the
level that causes the appearance of noise artefacts. Flow
was demonstrated in two perpendicular planes and con-
firmed by pulsed wave Doppler spectrum to exclude arte-
facts. Grey-Scale (GS) and PD signals were assigned to
each joint in accordance with semi-quantitative 0 to
3 scales [23]. An overall US score for GS and PD signal
was calculated at each US assessment as the sum of
either GS or PD signal scores obtained from each joint
(range 0 to 36).
Baseline CXCL13 levels were analysed in relation to
the proportion of patients achieving a total PD score ≤
1 at the 12-month assessment, recently tested as a cut-
off value for low level imaging activity [24]. As a more
stringent criterion, the achievement of a PD score = 0
[24] was also evaluated.
Statistical analysis
Data were described as mean and standard deviation
(SD) or median and interquartile range (IQR) if continu-
ous and as counts and percent if categorical. The preva-
lence of the considered outcomes was computed
together with their exact binomial 95% confidence inter-
vals (95% CI).
The associations of CXCL13 at study entry were
assessed with the Spearman R and 95% CI. A multiple
linear regression model, with robust standard errors,
was fitted to account for potential confounders (age at
diagnosis, gender, disease duration and ACPA positivity;
none collinear) and partial correlations were computed.
Model assumptions were checked by means of residual
analysis. Paired comparisons were performed with the
paired t test or the Wilcoxon sign rank test.
In outcome analyses, the CXCL13 values were cate-
gorised as low or high based on tertile distribution. The
association of high baseline CXCL13 (> 100 pg/ml, upper
tertile) with clinical and US outcomes at 12 months was
evaluated by means of univariable and multivariable
logistic models. The goodness of fit test was performed;
the c statistic was computed to assess model discrimina-
tion. The same confounders as above in addition to glu-
cocorticoid co-medication, the cumulative dose of MTX
and other possible predictors of clinical and US disease
activity (baseline clinical disease activity and PD scores)
were included. Similarly the association of baseline CRP
(> 2.3 mg/dl, upper tertile) and ESR (> 39 mm/h, upper
tertile) and the US outcome at 12 months was assessed
with logistic regression. Finally, the changes over time in
the prevalence of the clinical and US endpoints were
assessed with a logistic model for repeated measures,
while adjusting for baseline disease activity and treat-
ment. For post-hoc comparison at each time point the
Bonferroni correction was applied. All tests were two-
sided and the significance level was set at 5%. Stata 11.2
(StataCorp, College Station, TX, USA) was used for
computation.
Results
Baseline characteristics of the cohort
Clinical and US characteristics of the population at
study entry are summarised in Table 1. The patients
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had active disease as defined by a DAS ≥ 2.4 (mean 3.61
± 0.96) and median RA duration of three months (IQR
2 to 6) since their initial clinical symptoms. IgM RF and
IgG ACPA positivity was found in 57% and 49% of the
patients respectively. At US assessment, GS synovitis
was detected in 95% of the patients. A positive PD sig-
nal was observed in 76% of the cases, with a median PD
score of 3.5 (IQR 1 to 8).
Associations between CXCL13 and disease activity at
baseline
In cross-sectional analyses at baseline, serum levels of
CXCL13 appeared moderately, although significantly,
associated with both CRP (R 0.42, P < 0.001) and ESR
(R 0.41, P < 0.001) levels. Accordingly, CXCL13 behaved
as a biomarker of clinical disease activity, measured as
either the DAS or the SDAI. Among the core data set
measures, CXCL13 was most strongly associated with
the SJC (Table 2). The significant association remained
when adjustments for possible confounders (age at diag-
nosis, gender, disease duration and ACPA positivity)
were made (Table 2).
To confirm the association between CXCL13 and objec-
tive measures of joint inflammation, we also examined dis-
ease activity assessed by US. A significant correlation was
found with both GS and PD scores (Table 2). Again, the
significant association remained after accounting for
potential confounders (Table 2) as well as for CRP levels
(P < 0.001, data not shown).
In addition to its specific relationship with clinical and
US synovitis, CXCL13 showed further correlation with
the autoantibody status. Indeed, CXCL13 levels were
significantly higher in ACPA-positive compared to
ACPA-negative patients (median values 96.8 pg/ml (IQR
56.4 to 184.2) vs 68.5 pg/ml (IQR 43.5 to 105.9), P =
0.001). Differently from CXCL13, neither the ACPA sta-
tus nor ACPA titres were associated with clinical,
laboratory (ESR, CRP) and US measures of inflammation
in our cohort (data not shown).
Clinical and ultrasonographic follow-up of the cohort
By the end of the 12-month follow-up, 67% of the
patients were in DAS LDA (62% according to the SDAI)
and 41% in remission (11% according to the SDAI). Of
the 51 patients (33%) not achieving the target of LDA, 32
had started a combination therapy with anti-TNF accord-
ing to the treatment protocol. In the remaining 19
patients who did not achieve the target, combination
therapy with biological DMARDs was not initiated due to
contraindications, denied consent or evidence of disease
relapse after reaching LDA at previous visits.
The total PD score significantly fell over the study
period, with a mean decrease of 3.23 (95% CI 2.19 to
4.26; P < 0.001) at 6 months and 3.78 (95% CI 2.52 to
5.03; P < 0.001) at 12 months. In the overall cohort,
Table 1 Demographic, clinical and ultrasonographic data
of the study population at baseline
N = 161
Age, years, median (IQR) 64 (50 to 73)
F/M (%) 112/49 (69.6)
Disease duration, months, median (IQR) 3 (2 to 6)
DAS44, mean (± SD) 3.61 (0.96)
SDAI, mean (± SD) 31.53 (13.82)
SJC, median (IQR) 12 (8 to 18)
TJC, median (IQR) 12 (6 to 18)
RAI, median (IQR) 8 (5 to 11)
GH, 0 to 100 mm, median (IQR) 56 (50 to 73)
EGA, 0 to 10 cm, median (IQR) 4.6 (3.5 to 6)
PGA, 0 to 10 cm, median (IQR) 6 (4.8 to 8)
HAQ, median (IQR) 1.25 (0.75 to 1.88)
ESR, mm/h, median (IQR) 28.5 (17 to 46.5)
CRP, mg/dl, median (IQR) 1.19 (0.41 to 3.12)
IgM RF-positive, n. (%) 92 (57.1)
IgM RF titre, UI/ml, median (IQR) 69 (30.5 to 174)
IgG ACPA-positive, n. (%) 79 (49.1)
IgG ACPA titre, UI/ml, median (IQR) 100 (42.7 to 292.5)
US-GS score, median (IQR) 10 (5 to 12)
US-PD positive, n. (%) 122 (75.8)
US-PD score, median (IQR) 3.5 (1 to 8)
ACPA, anti-citrullinated protein antibodies; CRP, C-reactive protein; DAS44,
Disease Activity Score in 44 joints; EGA, evaluator global assessment of
disease activity; ESR, erythrocyte sedimentation rate; GH, global health
assessment; GS, Grey-Scale; HAQ, Health Assessment Questionnaire; Ig,
immunoglobulin; IQR, interquartile range; PD, Power Doppler; PGA, patient
global assessment of disease activity; RAI, Ritchie Articular Index; RF,
rheumatoid factor; SD, standard deviation; SDAI, Simplified Disease Activity
Score; SJC, swollen joint count; TJC, tender joint count; US, ultrasonography
Table 2 Associations between CXCL13 and clinical and








DAS44 0.35 (0.21 to 0.48) < 0.001 0.30 < 0.001
SDAI 0.28 (0.12 to 0.43) < 0.001 0.22 < 0.001
SJC 0.28 (0.12 to 0.43) < 0.001 0.26 < 0.001
TJC 0.10 (-0.06 to 0.26) 0.22 - -
RAI 0.12 (-0.04 to 0.28) 0.14 0.06 0.21
CRP 0.42 (0.29 to 0.54) < 0.001 0.38 < 0.001
ESR 0.41 (0.27 to 0.53) < 0.001 0.35 < 0.001
US-GS score 0.27 (0.10 to 0.44) 0.003 0.31 < 0.001
US-PD score 0.26 (0.08 to 0.42) 0.005 0.32 < 0.001
Results from Spearman R and multivariable linear regression analyses.
*Adjusted for age, gender, symptoms duration, ACPA positivity. CRP,
C-reactive protein; DAS44, Disease Activity Score in 44 joints; ESR, erythrocyte
sedimentation rate; RAI, Ritchie Articular Index; SDAI, Simplified Disease
Activity Score; SJC, swollen joint count; TJC, tender joint count; US-GS,
Grey-Scale; US-PD, Power Doppler
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78% of the patients showed low level US activity (PD ≤
1) at the end of follow-up, whilst PD = 0 was observed
in 61%. Among the patients achieving a final DAS < 2.4,
a PD signal > 1 persisted in 14% of the cases.
Associations between baseline CXCL13 and clinical
disease activity at follow-up
Baseline serum levels of CXCL13 were categorised as
low or high based on tertile distribution and were stu-
died in association with the rate of achievement of the
clinical outcomes at 12 months. Seventy-four patients
(71%) with low CXCL13 (first and second tertiles)
achieved DAS LDA at 12 months as compared to 30
(59%) with high CXCL13 (third tertile), with an adjusted
OR = 1.56 (95% CI 0.62 to 3.94, P = 0.35). This lack of
association was confirmed when considering as a sec-
ondary outcome disease remission, computed through
either the DAS or the SDAI (data not shown). As a
treatment protocol aimed at LDA may minimise clinical
differences due to more frequent therapeutic adjust-
ments in patients not achieving the target, we also
examined each time point separately. Overall, the preva-
lence of LDA increased over time, and was higher in the
low with respect to the high CXCL13 group (P < 0.001,
regression model for repeated measures, adjusted for
baseline DAS and treatment), although none of the post-
hoc comparisons at each time point reached statistical
significance (Figure 1A). The median number of thera-
peutic changes needed by the target protocol was 1(IQR
0 to 2) in the low and 2 (IQR 1 to 2) in the high
CXCL13 group (P < 0.001) and was independent of
baseline DAS and concomitant use of glucococorticoids.
Associations between baseline CXCL13 and
ultrasonographic disease activity at follow-up
The prevalence of PD ≤ 1 at different time points in the
low and the high CXCL13 group respectively is shown
in Figure 1B (regression model for repeated measures,
adjusted for baseline PD and treatment; P < 0.001). At
12 months assessment, the proportion of patients
achieving low-level imaging activity (PD ≤ 1) was signifi-
cantly lower in the third CXCL13 tertile (59% vs 88%,
P = 0.002), with an adjusted OR = 0.16 (95% CI 0.04 to
0.58, P = 0.005). The association of high CXCL13 levels
and PD persistence was independent of possible con-
founders (age, gender, disease duration, ACPA positivity,
glucocorticoid co-medication and the amount of MTX
administered) (Table 3). Notably, CXCL13 levels
emerged as the only baseline predictor of US outcomes in
our cohort. Indeed, neither CRP nor ESR levels as well as
baseline PD scores (all categorised as low or high based on
tertile distribution) appeared predictive of the residual
imaging activity at 12 months (Table 3). Results were con-
firmed when considering as an outcome measure the total
suppression of PD signal (PD score = 0). The proportion
of patients achieving a final PD score = 0 was 70% in the
low CXCL13 group compared to 44% in the upper
CXCL13 tertile (P = 0.02), with an OR = 0.31 (95% CI
0.13 to 0.74, P = 0.009). The association became border-
line non-significant (P = 0.08) after adjusting for pertinent
confounders, such as the cumulative treatment and ACPA
status (data not shown).
CXCL13 baseline levels could further discriminate dif-
ferent US outcomes among patients achieving DAS <
2.4 at 12 months. Indeed, the high CXCL13 group less
frequently reached low level imaging activity (PD ≤ 1)
despite clinical LDA (65% vs 98%, P = 0.002), with an
adjusted OR = 0.06 (95% CI 0.01 to 0.55, P = 0.01).
Again, CXCL13 levels appeared the only baseline predic-
tor of PD residual inflammation in patients in clinical
LDA (Table 3).
Discussion
The identification of novel markers measurable in acces-
sible compartments and capable of predicting relevant
outcomes in early RA is a critical issue with direct impli-
cations in routine clinical practice as well as in enhancing
our understanding of the pathobiological processes of the
disease. In this study, we provide first time evidence that
systemic measurement of the lymphoid chemokine
CXCL13 can be exploited to predict synovitis outcomes
in patients with recent-onset RA. We demonstrate that,
within a structured treat-to-target protocol, baseline
serum levels of CXCL13 associate with the severity of
synovitis as assessed by US and predict PD persistence
after 12 months in response to conventional treatments.
The particular setting of an inception cohort of early RA
patients (< 12 months from symptom onset), untreated
at baseline and homogeneously treated with MTX mono-
therapy according to a steering strategy enabled us: a) to
minimise the influence of possible confounders, such as
disease duration and type of medication, on CXCL13
specific associations and predictive values, and b) to
determine its cross-sectional and prognostic significance
in a “real-life” clinical platform.
In keeping with previous data [17,18], CXCL13 levels
at baseline (before treatment) were confirmed to associ-
ate with clinical and laboratory measures of disease
activity. In particular, CXCL13 appeared as a marker of
synovitis, as assessed clinically and, more relevantly, by
US. Correlations with imaging synovitis have been also
found for ESR and CRP [25,26]. However, an improved
face validity of CXCL13 as a marker compared to acute
phase proteins is that this chemokine can be induced
directly within the rheumatoid joint, where it associates
with the development of lymphoid follicles and germinal
centre reactions [27,28]. Although serum CXCL13 may
originate from a variety of different sources, including
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lymph nodes where CXCL13 is constitutively produced
[11,12] and which can exhibit aspects of reactivity in
association with active RA [29], the inflamed synovial
tissue appears to significantly contribute to the systemic
up-regulation of the chemokine [15]. In contrast, the
acute phase proteins are primarily produced by hepato-
cytes in response to interleukins released during inflam-
mation [30]. Thus, measurement of CXCL13 levels may
provide an advantage in the objective assessment of the
degree of synovitis compared to routine markers that
Figure 1 Clinical and ultrasonographic outcomes over time according to baseline CXCL13 levels. Baseline CXCL13 levels and progressive
achievement of clinical and ultrasonographic (US) outcomes in patients with recent-onset rheumatoid arthritis treated within a structured treat-
to-target protocol aiming at low disease activity. Patients were divided into tertiles based on CXCL13 levels. The proportion of patients achieving
low disease activity (DAS < 2.4) (A) and a power Doppler score ≤ 1 at ultrasonography (B) at each time point for different CXCL13 thresholds is
shown. The mean ± SD CXCL13 levels were 163.6 ± 63.27 pg/ml for the third tertile (lowest value 99.83 pg/ml), 73.57 ± 12.08 pg/ml for the
second tertile and 38.44 ± 10.42 pg/ml for the first tertile. Due to the lack of significant differences between the first and the second CXCL13
tertile, clinical and US outcomes are presented together against the third tertile. Values are the mean ± SD.
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only indirectly are linked to joint inflammation. As it is
now widely accepted that US is more accurate than
standard clinical examination at detecting synovitis [25],
and PD technologies further improve the capability of
identifying actively inflamed joints [31], the association
with PD scores found here makes CXCL13 a valuable
surrogate marker for quantitative assessment of objec-
tive and pathologically relevant disease processes in RA.
The specific association with US parametres might
explain why CXCL13 assessment at baseline was still
associated with synovitis evolution at 12 months in our
cohort. Patients with CXCL13 levels in the highest tertile
(> 100 pg/ml), although comparable to patients in lower
tertiles in the rate of achievement of clinical LDA in the
context of a treat-to-target strategy, required more fre-
quent dose adjustments of MTX and, accordingly,
showed delays in the accomplishment of treatment goals.
Even more relevantly, the likelihood of suppression of
joint inflammation, as assessed by US measurement of
PD signal, was reduced for higher CXCL13 baseline
levels. The predictive value of CXCL13 appears of utmost
clinical importance when considering patients in LDA
states, in which different thresholds of residual imaging
synovitis might be of importance for subsequent clinical
and radiological evolution [4-6]. Notwithstanding the
association of CXCL13 with CRP levels as well as the
ACPA-status, both regarded as indicators of less favour-
able outcomes in RA [32,33], PD activity at 12 months in
our cohort was uniquely explained by different levels of
the chemokine. Thus, from a clinical perspective, the
assessment of baseline CXCL13 provides information on
a relevant measure of disease severity not yet predicted
by routine variables.
Collectively, our results fully fit with recent observations
from Meeuwisse et al. [18], providing direct explanation of
their potential biological basis. In Meeuwisse’s study [18],
higher CXCL13 levels were reported to be associated with
increased rates of joint destruction in the long term.
Although radiographic outcomes in our cohort could not
be determined, our data complete previous findings
demonstrating that CXCL13 is associated with the inten-
sity of active joint inflammation as assessed by PD. The
relationship between imaging-detected synovitis and sub-
sequent structural damage is well established. Reports of
several longitudinal studies [31,34,35] have described the
persistent PD signal in affected joints being a predictor of
radiologic progression in RA. The higher rates of PD sig-
nal persistence that we report in patients in the third
CXCL13 tertile, thus fully fit with increased progression of
radiographic damage. Meeuwisse et al. [18] also reported
that higher CXCL13 levels were predictive of significantly
lower chances of achieving drug-free remission during
seven years’ follow-up. Persistence of a PD signal above
low imaging activity in these patients provides a possible
explanation, as US signs of ongoing inflammation are
associated with unstable remission and short-term disease
relapses [6]. Also, later time points at which LDA were
attained during the first year of the disease in patients in
the third CXCL13 tertile in our cohort further justify
lower rates of drug-free remission. Indeed, it is well estab-
lished that one of the major determinants of good clinical
outcomes is the time that elapses to achieve the outcome
itself [36,37].
Although the results of this study provide a solid
foundation for our conclusions, the study does have
some limitations. Definite confirmation of the specific
Table 3 Predictors of low power Doppler activity (≤ 1) at 12 months
Univariable analyses Multivariable analyses*
OR (95%CI) P OR (95% CI) P
Overall population
CXCL13 third tertile 0.19 (0.07 to 0.54) 0.002 0.16 (0.04 to 0.58) 0.005
CRP third tertile 0.58 (0.21 to 1.56) 0.28 - -
ESR third tertile 0.61 (0.22 to 1.7) 0.35 - -
ACPA (positive) 0.40 (0.14 to 1.15) 0.09 0.41 (0.12 to 1.40) 0.15
baseline PD score (third tertile) 0.94 (0.31 to 2.83) 0.91 - -
DAS < 2.4
CXCL13 third tertile 0.05 (0.01 to 0.42) 0.006 0.06 (0.01 to 0.55) 0.01
CRP third tertile 0.53 (0.12 to 2.37) 0.41 - -
ESR third tertile 1.22 (0.22 to 6.72) 0.82 - -
ACPA (positive) 0.46 (0.09 to 2.22) 0.33 - -
baseline PD score (third tertile) 0.57 (0.11 to 2.86) 0.49 - -
*Adjusted for age, gender, symptoms duration, glucocorticoid comedication, total amount of methotrexate administered and each of the variables with P < 0.2 in
univariable analysis.
ACPA, anti-citrullinated protein antibodies; CRP, C-reactive protein; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; PD, Power Doppler. CXCL13
third tertile: > 100 pg/ml. CRP third tertile: > 2.3 mg/dl. ESR third tertile: > 39 mm/1 h baseline PD score third tertile: > 7
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relationship between serum CXCL13 and PD synovitis
would require paired longitudinal assessments at each
time point during follow-up, a possibility that was lim-
ited in our study due to the unavailability of serum sam-
ples matched with US at follow-up. Another relevant
issue remains the direct demonstration of the histo-
pathological correlates of serum CXCL13 in relation to
specific synovial cell populations and inflammatory
patterns, which is currently being developed in our
laboratory. As synovial CXCL13 protein and mRNA
associate with lymphocyte infiltration [38], the assess-
ment of CXCL13 levels in the peripheral circulation
might turn out as a comprehensive, non-invasive tool to
gain further information on the clinical significance of
synovial tissue heterogeneity in RA [39,40].
Conclusions
The Outcome Measures in Rheumatology (OMERACT)
group continues to develop validation criteria for a soluble
biomarker which reflects relevant outcomes in RA [41].
Although different sources of variation in serum levels
have to be further investigated, CXCL13 is acquiring
increasing validity as a new soluble marker in RA accord-
ing to the OMERACT filter. The relationship between
CXCL13 and an objective measure of synovitis, such as
US-PD, as well as its independent predictive value for PD
persistence within an unselected cohort of patients with
recent onset RA that we report in this study add robust-
ness to previous data. Our findings appear further
strengthened by the plausible biological explanation that
links CXCL13 with synovial pathology. In conclusion, we
suggest that CXCL13 is a promising prognostic marker in
early RA, accurate in assessing the severity of synovitis and
its persistence over time in response to conventional
treatments.
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